NCT07019337View on ClinicalTrials.gov

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

December 31, 2030

Conditions

HER2-positive Breast CancerMetastatic Breast Cancer

Interventions

DRUG

Pyrotinib

400mg or 320mg qd

DRUG

Capecitabine

500mg tid

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER